mercredi 12 septembre 2018

Onco Actu du 12 septembre 2018


1. Biologie

Understanding the geography of triple negative breast cancer [Stanford Medicine]

Lasker Awards Recognize Work on Histones, Anesthesia, RNA [The Scientist]

Histone Modifications: Insights into Their Influence on Gene Expression [Cell]

5. Traitements

Are We Being Misled About Precision Medicine? [NY Times]

5.1 Traitements - Pré-clinique

This gene mutation is key to glioblastoma’s ‘immortality’ and could point to drug targets [FierceBiotech]

Researchers Unlock Secret of Deadly Brain Cancer’s “Immortality” [UCSF]

5.12.3 Immunothérapies-combinaisons

Can Pfizer and Merck KGaA parlay Bavencio combo data into a kidney cancer win? [FiercePharma]

Bavencio® (Avelumab) Plus Inlyta® (Axitinib) Significantly Improved Progression-Free Survival In Previously Untreated Patients With Advanced Renal Cell Carcinoma In Phase III Study [Pfizer]

5.2 Pharma

Minimal Residual Disease Negativity Data, a Measure of Undetectable Disease, Added to VENCLEXTA® (venetoclax tablets) Label [AbbVie]

Health-Related Quality of Life Maintained with Addition of ERLEADA to Androgen Deprivation Therapy for Patients with Non-Metastatic Castration-Resistant Prostate Cancer [Janssen]

5.2.1 Pharma - Partenariats

Incyte and Foundation Medicine Announce Agreement to Develop Companion Diagnostic for Pemigatinib (INCB54828), a Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma [Incyte]

5.4 Traitements - Economie

NICE Issues Evidence-Based Recommendations on Lenvatinib and Sorafenib for Treatment of Differentiated Thyroid Cancer [ESMO]

6. Lutte contre les cancers

Integrating Geriatric Assessment into Cancer Care: A Conversation with Dr. Supriya Mohile [NCI]

6.1 Observation

Hispanic Children More Likely to Experience Neurotoxicity During Treatment for Acute Lymphoblastic Leukemia [AACR]

6.11 Patients

Improving Cancer Diagnosis and Care Patient Access to Oncologic Imaging and Pathology Expertise and Technologies: Proceedings of a Workshop [National Academies Press]

6.9 Controverses

The CRISPR patent decision didn’t get the science right. That doesn’t mean it was wrong [STAT]